Egner, P.A., Chen, J.G., Wang, J.B., Wu, Y., Sun, Y., Lu, J.H., Zhu, J., Zhang, Y.H., Chen, Y.S., Friesen, M.D., Jacobson, L.P., Muñoz, A., Ng, D., Qian, G.S., Zhu, Y.R., Chen, T.Y., Botting, N.P., Zhang, Q., Fahey, J.W., Talalay. P., Groopman. J.D. and Kensler, T.W. (2011) Bioavailability of Sulforaphane from Two Broccoli Sprout Beverages: Results of a Short-Term, Cross-Over Clinical Trial in Qidong, China. Cancer Prevention Research (Philadelphia), 4, 384-395.
http://dx.doi.org/10.1158/1940-6207.CAPR-10-0296

has been cited by the following article:

• TITLE: Low-Dose of the Sulforaphane Precursor Glucoraphanin as a Dietary Supplement Induces Chemoprotective Enzymes in Humans

  AUTHORS: Yusuke Ushida, Hiroyuki Suganuma, Akinori Yanaka

  KEYWORDS: Sulforaphane, Glucoraphanin, Chemoprotection, Broccoli Sprout, Phase 2 Enzymes

  JOURNAL NAME: Food and Nutrition Sciences, Vol.6 No.17, December 23, 2015

  ABSTRACT: Broccoli sprout (BS) supplements have been marketed for over a decade for the promising health beneficial effects of sulforaphane (SFN), which induces Nrf2 signaling and downstream chemoprotective genes, including phase 2 enzymes. Most commercially available BS supplements encapsulate heat-processed BS containing glucoraphanin (GR), which is hydrolyzed to SFN by the intestinal microbiota. However, the absorption behavior of SFN following the intake of such BS supplements is still unclear. Additionally, the GR dose (around 30 mg) recommended by many manufacturers of BS supplements is relatively lower than the effective dose determined in previous intervention studies. The aims of this study were to assess the effects of a single administration of a typical BS supplement containing lower doses of GR (30 or 60 mg from 3 or 6 capsules, respectively) on SFN absorption, and also to assess the serum activities of phase 2 enzymes as possible surrogate markers of the beneficial effects of SFN. Urinary excreted isothiocyanates and dithiocarbamates showed that the SFN absorption following administration of BS supplement was prolonged and varied among individuals, which conforms to the well-known characteristics of intestinal microbiota-mediated SFN absorption. The amount of SFN absorbed increased dose-dependently but not linear fashion (9.27 μmol and 13.5 μmol for 3 and 6 capsules, respectively). There was no significant difference in SFN bioavailability and the number of capsules consumed. Serum activities of phase 2 enzymes glutathione S-transferase (GST) and NAD(P)H: quinone oxidoreductase 1 (NQO1), which have been reported to display “chemoprotected states” in organs such as the liver, were dose-dependently and synchronously elevated (p